Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms UNCOVER-2
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 21 Mar 2023 Results of post-hoc pooled analysis assessing NPF treatment targets in the overall population, and biologic-experienced and -naive subpopulations across IXORA-R, IXORA-S, integrated UNCOVER-2-3 presented at the American Academy of Dermatology annual Meeting 2023
    • 21 Mar 2023 Results of post-hoc pooled analysis assessing patient-reported fatigue, using the SF-36 vitality domain, in patients who received ixekizumab 80 mg Q2W for 12 weeks for moderate-to-severe psoriasis across UNCOVER-1 (N=433), UNCOVER-2 (N=351), UNCOVER-3 (N=385), and IXORA-S (N=136) SPIRIT-H2H presented at the American Academy of Dermatology annual Meeting 2023
    • 21 Mar 2023 Results of post-hoc pooled analysis assessing the disease improvement and clearance of palmoplantar PsO in the palms and soles of patients with moderate-to-severe plaque PsO and baseline palmoplantar PsO who were treated with ixekizumab for up to 5 years across 6 clinical trials (NCT01474512, NCT01597245, NCT01646177, NCT03364309, NCT02561806 and NCT03073200), presented at the American Academy of Dermatology annual Meeting 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top